ThrombozytenaggregationshemmerWelche soll ich wann verordnen? Und wie sieht es mit einer gleichzeitigen Antikoagulation aus?Platelet Aggregation InhibitorsWhat Should I Prescribe When? And what about a Simultaneous Anticoagulation?

[1] Secemsky E(2017)Dual Antiplatelet Therapy (DAPT) Study Investigators. Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting JAMA Cardiol 2 478-87

[2] Yeh R(2013)Risk of bleeding on triple antithrombotic therapy after percutaneous coronary interven-tion/stenting: a systematic review and meta-analysis Cardiol 29 204-12

[3] Kereiakes D(2017)The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials Int J Cardiol 235 73-86

[4] Andrade J(2017)Impact of design of coronary stents and length of dual anti-platelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients Europ Heart J 38 3160-72

[5] Deyell M(1999)Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events Drug Saf 21 325-35

[6] Khoo C(2019)Optimal duration of aspirin plus clopidogrel after ischemic stroke or transient ischemic attack. A systematic review and meta-analysis Stroke 50 947-53

[7] Lee M(2007)TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2001-15

[8] Humphries K(2012)TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 1297-309

[9] Cairns J(2009)PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 1045-57

[10] Wang W(2015)PEGASUS-TIMI 54 investigators. Long-term use of ticagrelor in patients with prior myocardial infarction NEJM 372 1791-1800

[1] Secemsky E(2017)Dual Antiplatelet Therapy (DAPT) Study Investigators. Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting JAMA Cardiol 2 478-87

[2] Yeh R(2013)Risk of bleeding on triple antithrombotic therapy after percutaneous coronary interven-tion/stenting: a systematic review and meta-analysis Cardiol 29 204-12

[3] Kereiakes D(2017)The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials Int J Cardiol 235 73-86

[4] Andrade J(2017)Impact of design of coronary stents and length of dual anti-platelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients Europ Heart J 38 3160-72

[5] Deyell M(1999)Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events Drug Saf 21 325-35

[6] Khoo C(2019)Optimal duration of aspirin plus clopidogrel after ischemic stroke or transient ischemic attack. A systematic review and meta-analysis Stroke 50 947-53

[7] Lee M(2007)TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2001-15

[8] Humphries K(2012)TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 1297-309

[9] Cairns J(2009)PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 1045-57

[10] Wang W(2015)PEGASUS-TIMI 54 investigators. Long-term use of ticagrelor in patients with prior myocardial infarction NEJM 372 1791-1800